Business Wire

Merz and Teijin Announce Partnership to Bring Xeomin® (incobotulinumtoxinA) to Japan

Jaa

Merz, a global leader in aesthetics and neurotoxins, and Teijin Limited, a technology-driven global group operating in the fields of materials, healthcare, and IT businesses, announced today that they have entered into a strategic license and co-development agreement for the commercialization of Xeomin® (incobotulinumtoxinA) for Japan.

“We believe Xeomin® will become the core product of the Teijin Group’s healthcare business, which aims to provide a total solution for stroke patients with the synergistic effects of our stroke related products and pipeline such as rehabilitation devices and regenerative medical products, “ said Akihisa Nabeshima, President, Teijin Pharma Limited. “We are extremely pleased to be establishing a partnership with Merz, whose long, successful history in neurotoxins focus shows a good strategic fit with our own.“

“In Teijin, Merz has found an exceptionally strong partner whose strength in both neurology and the rehabilitation space demonstrates an excellent strategic fit with Merz’s neurotoxin focus,” said Philip Burchard, CEO – Merz. “We are very pleased to enter this collaboration with Teijin in this highly important market, which we hope will enable us to bring neurotoxin therapy to additional patients and fulfill a key need in Japan.”

Xeomin® (incobotulinumtoxinA) was approved for use in the treatment of patients with dystonia and blepharospasm by the European regulatory authorities in 2005 and by the U.S. FDA in 2010. The product has been approved for post-stroke spasticity of the upper limb in Europe since 2009, with FDA approval for the adult upper limb spasticity indication granted in 2015. Xeomin® (incobotulinumtoxinA) is marketed in 50 countries around the world. Merz uses state-of-the-art technology in its dedicated, FDA-approved facility in Dessau, Germany, meeting the highest international standards for biologic manufacturing.

Under the terms of the agreement, Merz will receive an upfront payment in addition to milestones and royalties. Merz is currently sponsoring two clinical trials in Japan covering spasticity of both upper and lower limbs, and the upper limb trial is expected to be completed in 2018. Teijin Pharma Limited, the core company of Teijin Group’s healthcare business will prepare and file the marketing approval application. Upon the marketing approval of Xeomin® (incobotulinumtoxinA), Merz will be responsible for the product manufacturing and supply and Teijin Pharma will manage commercial activities in Japan.

“Merz has a long history of successful partnerships both in Japan and around the world, and we continue to actively seek opportunities to collaborate with well-matched strategic partners such as Teijin,” said Jörg Bergler, Global Head of Corporate Development for Merz. “Teijin Pharma is a growing player within rehabilitation in Japan, and has shown a strong track record of product maximization and market expansion in their Pharmaceutical business, and Merz looks forward to a productive and successful relationship with them for many years to come.”

About Merz

With approximately 3,000 employees and 34 subsidiaries, Merz is a leading global provider in the fields of Aesthetics and Neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. In addition to its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy to treat neurologically induced movement disorders. OTC medicines, dietary supplements and skincare products round off the offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2015/16, the Merz Pharma Group generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has some 170 companies and around 19,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY741.3 billion (USD 6.5 billion) and total assets of JPY 964.1 billion (USD 8.5 billion) in the fiscal year ending March 31, 2017. Please visit www.teijin.com .

Contact information

Merz Contact:
Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Email: mariana.smith@merz.com
or
Teijin Contact:
Corporate Communications
Teijin Limited
Phone: +81 3 3506 4055
Email: pr@teijin.co.jp

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

FastForward.ai Launches “Ooredoo Next”, Myanmar’s New Digital Engagement Platform16.8.2018 13:15Tiedote

FastForward.ai launched today Ooredoo Next, the new digital engagement platform for Ooredoo Myanmar. Supported by FastForward NXTTM real-time API platform featuring artificial intelligence and machine learning, Ooredoo Next allows all mobile users in Myanmar to easily engage with Ooredoo brand inside Facebook Messenger using real-time automated answers. For Ooredoo Myanmar, FastForward.ai digital engagement platform enables efficient management of social media advertising campaigns, customer relationship management and monetization. Augie K. Fabela II, Co-Founder and CEO, FastForward.ai said: “We bring Silicon Valley user experience to the Telco world. We enable mobile operators to give their customers 100% control of their choices: they decide the services they want to use, how and when they want to use them." Romeo S. Ganescu, Co-Founder and Chief Product Officer, FastForward.ai said: “The future of mobile engagement lies inside social and messaging networks and our FastForward NXTTM

In the Wake of the Ongoing Floods in Kerala; UAE Exchange and Unimoni Waive Service Fee on Remittances to Kerala Chief Minister's Distress Relief Fund16.8.2018 12:30Tiedote

Leading money transfer, foreign exchange and payment solutions brands, UAE Exchange and Unimoni, have waived service fee on remittances to Kerala Chief Minister's Distress Relief Fund in the wake of the catastrophic floods that has ravaged the Indian state of Kerala. The initiative which enables the global Indian diaspora to contribute to the relief efforts, follows a personal contribution of two crore rupees made by the Group Chairman and noted UAE-based businessman and philanthropist, Dr. Bavaguthu Raghuram Shetty, to help those affected by the floods. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180816005229/en/ Promoth Manghat, Executive Director, Finablr and Group CEO (Photo: AETOSWire) Promoth Manghat, Executive Director, Finablr and Group CEO, said, “As a committed corporate citizen, who firmly believes in helping communities in times of need, it was our responsibility to do all that is in our power to aid the peopl

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 08:00Tiedote

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 07:05Tiedote

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth16.8.2018 02:40Tiedote

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy16.8.2018 01:37Tiedote

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme